Tag: Biopharmaceutical

AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.

"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."

Wake Tech breaks ground on a $60M Advanced Technology Center in Wendell, offering state-of-the-art biopharma and manufacturing training. Opens spring ...

"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."

Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...

Explore the intriguing stock volatility of Japer Therapeutics on NASDAQ as it experiences notable fluctuations, urging investors to delve deeper ...

Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...

Fortress Biotech's Q3 earnings per share of -53 cents exceeded the analyst estimate of -$1.97 while revenue of $19.95 million ...

Fortress Biotech Inc's shares dropped 27.9% this quarter, exceeding analysts' predicted loss of $1.97 per share.

Discover the financial insights of Dermira, a biopharmaceutical company, and gain a deeper understanding of their stock performance and market ...